サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1427785

ドキソルビシンの世界市場レポート 2024

Doxorubicin Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ドキソルビシンの世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

ドキソルビシンの市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には6.7%の年間複合成長率（CAGR）で17億1,000万米ドルに成長すると予想されます。予測期間で予想される成長は、個別化医療の進歩、標的ドラッグデリバリーシステムの開発、免疫療法の組み合わせ、ゲノミクスとバイオマーカーの進行中の調査、精密腫瘍学の拡大に起因すると考えられます。予測期間中に予想される主な動向には、ナノテクノロジーの統合、併用療法の重視、バイオシミラー市場の拡大、補助療法への注目、心臓保護のための介入などが含まれます。

がんの罹患率の増加により、ドキソルビシン市場が前進しています。異常で制御されていない細胞増殖を特徴とするがんは、化学療法を必要とする一連の疾患であり、一般的な抗生物質であるドキソルビシンは、がん細胞のDNAを損傷することによってさまざまな種類のがんを治療するために使用されます。がん罹患率の急増により、ドキソルビシンの需要が高まっています。たとえば、2021年の米国がん協会の報告書では、2020年に新たにがんと診断された症例が180万件であることが明らかになりました。さらに、国立がん研究所による2020年9月のデータでは、新たながん症例が1,806,590件で、米国男性のがん診断全体の43％を占めていることが示されています。 2020年は、前年の2019年の1,752,735人から増加しました。したがって、がん患者の増加がドキソルビシン市場の原動力となっています。

遺伝性疾患の増加は、将来ドキソルビシン市場の成長を促進すると予想されます。新生児スクリーニングは、出生直後のすべての新生児の特定の健康状態を評価する手順であり、健康上のニーズを早期に特定し、それに対処する上で重要な役割を果たします。 ドキソルビシンは、新生児スクリーニングによって乳がんや卵巣がんを発症するリスクが高いと特定された乳児の予防策に利用できます。 2022年にテキサス州保健局は、新生児スクリーニングのために受け取った検体が4.3%増加し、2021年の72万9,347件から2022年には76万1,000件に増加したと報告しました。さらに、39万4,000人の乳児が検査を受け、1,130人の乳児が新生児スクリーニングのいずれかに罹患していることが判明しました。 2022年のNBS疾患。このように、遺伝性疾患の急増がドキソルビシン市場の成長に貢献しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のドキソルビシン市場、医薬品製剤別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 凍結乾燥粉末
  • ドキソルビシン注射
  • 世界のドキソルビシン市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 乳がん
  • 腎臓がん
  • 肝臓がん
  • 肉腫
  • 卵巣がん
  • 肺がん
  • 白血病
  • 多発性骨髄腫
  • その他の用途
  • 世界のドキソルビシン市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 地域および国の分析

  • 世界のドキソルビシン市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界のドキソルビシン市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ドキソルビシン市場の競合情勢
  • ドキソルビシン市場の企業プロファイル
    • Pfizer Inc.
    • Johnson and Johnson（Janssen Pharmaceutical）
    • Baxter International Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Hospira Inc.

第31章 その他の大手および革新的な企業

  • Dr. Reddy's Laboratories Ltd.
  • Cipla Limited
  • Hikma Pharmaceuticals
  • Mylan Pharmaceuticals Inc.
  • VHB Life Sciences Limited
  • Xi'an International Healthcare Factory Co.Ltd.
  • Accord Healthcare Ltd.
  • TTY Biopharm Company Limited
  • Cadila Pharmaceuticals
  • Neon Laboratories Limited
  • Zydus Group
  • Ortho Biotech Products LP
  • APP Pharmaceuticals Manufacturing LLC
  • Sun Pharmaceutical Industries Ltd.
  • Transo-Pharm Handels GmbH

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13629

Doxorubicin, a potent chemotherapy medication, falls under the class of drugs known as anthracyclines. It operates by disrupting the synthesis of DNA and RNA in cancer cells, hindering their growth and division. This drug is employed in the chemotherapy treatment of various cancer types.

Doxorubicin is available in two main forms lyophilized powder and doxorubicin injection. Lyophilized doxorubicin powder denotes a freeze-dried version of the chemotherapy drug, where the water content has been removed. Lyophilization is utilized to enhance preservation, ensuring the drug's stability and longevity. These formulations find application in the treatment of breast cancer, kidney cancer, liver cancer, sarcoma, ovarian cancer, lung cancer, leukemia, multiple myeloma, among others, and are accessible through hospital pharmacies, retail pharmacies, and online pharmacies.

The doxorubicin market research report is one of a series of new reports from The Business Research Company that provides doxorubicin market statistics, including the doxorubicin industry's global market size, regional shares, competitors with a doxorubicin market share, detailed doxorubicin market segments, market trends, and opportunities, and any further data you may need to thrive in the doxorubicin industry. This doxorubicin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The doxorubicin market size has grown strongly in recent years. It will grow from $1.23 billion in 2023 to $1.32 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historical period can be ascribed to advancements in chemotherapy, adherence to oncology treatment standards, clinical effectiveness, increased rates of patient survival, and recommendations from physicians.

The doxorubicin market size is expected to see strong growth in the next few years. It will grow to $1.71 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The anticipated growth in the forecast period can be attributed to advancements in personalized medicine, the development of targeted drug delivery systems, combinations of immunotherapy, ongoing research in genomics and biomarkers, and the expansion of precision oncology. Major trends expected in the forecast period include the integration of nanotechnology, emphasis on combination therapies, expansion of the biosimilar market, focus on adjuvant therapy, and interventions for cardioprotection.

The increasing prevalence of cancer is propelling the doxorubicin market forward. Cancer, characterized by abnormal and uncontrolled cell growth, is a group of diseases that necessitates chemotherapy, where doxorubicin, a common antibiotic, is employed to treat various cancer types by impairing the DNA of cancer cells. The surge in cancer incidence has resulted in a heightened demand for doxorubicin. For example, the 2021 American Cancer Society report revealed 1.8 million new cancer cases diagnosed in 2020. Additionally, data from September 2020 by the National Cancer Institute indicated 1,806,590 new cancer cases, constituting 43% of all cancer diagnoses in men in the United States in 2020, up from 1,752,735 in the previous year, 2019. Hence, the growing prevalence of cancer patients is a driving force for the doxorubicin market.

The increase in genetic disorders is anticipated to drive the growth of the doxorubicin market in the future. Newborn screening, a procedure that assesses all newborns shortly after birth for specific health conditions, plays a crucial role in identifying and addressing health needs early on. Doxorubicin can be utilized in preventive measures for infants identified as high-risk for developing breast and ovarian cancer through newborn screening. In 2022, the Texas Department of State Health Services reported a 4.3% increase in specimens received for newborn screening, rising from 729,347 in 2021 to 761,000 in 2022. Moreover, 394,000 babies were screened, with 1,130 babies found to be affected by one of the NBS disorders in 2022. Thus, the surge in genetic disorders is contributing to the growth of the doxorubicin market.

Advancements in drug investigation represent a prominent trend gaining traction in the doxorubicin market. Leading companies within the doxorubicin market are actively engaged in developing cutting-edge technologies to introduce advanced products such as injections, aiming to fortify their market position. An illustrative example is the approval granted to Padagis, a US-based healthcare company, for its AB-rated generic version of Doxil (Doxorubicin Liposome Injection) by the US Food and Drug Administration in October 2021. This anthracycline topoisomerase inhibitor is utilized in the treatment of ovarian cancer, sarcoma, multiple myeloma, and in conjunction with bortezomib for multiple myeloma treatment. Doxorubicin liposome acts as an antineoplastic agent.

Major players in the doxorubicin market are strategically focusing on innovative drug development to enhance their market standing. Notably, in May 2023, Dr. Reddy's Laboratories, an India-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for the launch of Doxorubicin Hydrochloride Liposome Injection in the US market. This treatment targets ovarian and breast cancer, providing patients with a new therapeutic option. The approval process involved pre-clinical studies, clinical trials, and the submission of a New Drug Application (NDA) to the FDA to demonstrate the drug's safety and efficacy.

In November 2021, Pfizer Inc., a US-based multinational biopharmaceuticals company, acquired Trillium Therapeutics in an undisclosed deal. This strategic acquisition expanded Pfizer's portfolio with a clinical-stage range of oncology drugs, reinforcing its presence in the field of oncology. Trillium Therapeutics, based in Canada, specializes in the development of clinical-stage doxorubicin-based drug therapies for hematological malignancies.

Major companies operating in the doxorubicin market report are Pfizer Inc., Johnson and Johnson, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Hospira Inc., Dr. Reddy's Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals, Mylan Pharmaceuticals Inc., VHB Life Sciences Limited, Xi'an International Healthcare Factory Co. Ltd., Accord Healthcare Ltd., TTY Biopharm Company Limited, Cadila Pharmaceuticals, Neon Laboratories Limited, APP Pharmaceuticals Manufacturing LLC, Sun Pharmaceutical Industries Ltd., Transo-Pharm Handels GmbH, LGM Pharma, Zhejiang Hisun Pharma, Actavis Pharma, Celon Laboratories Limited, Samarth Life Sciences Pvt. Ltd

North America was the largest region in the doxorubicin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the doxorubicin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the doxorubicin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The doxorubicin market consists of sales of doxorubicin hydrochloride injections, adriamycin, doxil, myocet. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Doxorubicin Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on doxorubicin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for doxorubicin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The doxorubicin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug Formulation: Lyophilized Powder; Doxorubicin Injection
  • 2) By Application: Breast Cancer; Kidney Cancer; Liver Cancer; Sarcoma; Ovarian Cancer; Lung Cancer; Leukemia; Multiple Myeloma; Other Applications
  • 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
  • Companies Mentioned: Pfizer Inc.; Johnson and Johnson; Baxter International Inc.; Teva Pharmaceutical Industries Ltd.; Hospira Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Doxorubicin Market Characteristics

3. Doxorubicin Market Trends And Strategies

4. Doxorubicin Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Doxorubicin Market Size and Growth

  • 5.1. Global Doxorubicin Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Doxorubicin Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Doxorubicin Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Doxorubicin Market Segmentation

  • 6.1. Global Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Lyophilized Powder
  • Doxorubicin Injection
  • 6.2. Global Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Breast Cancer
  • Kidney Cancer
  • Liver Cancer
  • Sarcoma
  • Ovarian Cancer
  • Lung Cancer
  • Leukemia
  • Multiple Myeloma
  • Other Applications
  • 6.3. Global Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

7. Doxorubicin Market Regional And Country Analysis

  • 7.1. Global Doxorubicin Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Doxorubicin Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Doxorubicin Market

  • 8.1. Asia-Pacific Doxorubicin Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Doxorubicin Market

  • 9.1. China Doxorubicin Market Overview
  • 9.2. China Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Doxorubicin Market

  • 10.1. India Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Doxorubicin Market

  • 11.1. Japan Doxorubicin Market Overview
  • 11.2. Japan Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Doxorubicin Market

  • 12.1. Australia Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Doxorubicin Market

  • 13.1. Indonesia Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Doxorubicin Market

  • 14.1. South Korea Doxorubicin Market Overview
  • 14.2. South Korea Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Doxorubicin Market

  • 15.1. Western Europe Doxorubicin Market Overview
  • 15.2. Western Europe Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Doxorubicin Market

  • 16.1. UK Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Doxorubicin Market

  • 17.1. Germany Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Doxorubicin Market

  • 18.1. France Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Doxorubicin Market

  • 19.1. Italy Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Doxorubicin Market

  • 20.1. Spain Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Doxorubicin Market

  • 21.1. Eastern Europe Doxorubicin Market Overview
  • 21.2. Eastern Europe Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Doxorubicin Market

  • 22.1. Russia Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Doxorubicin Market

  • 23.1. North America Doxorubicin Market Overview
  • 23.2. North America Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Doxorubicin Market

  • 24.1. USA Doxorubicin Market Overview
  • 24.2. USA Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Doxorubicin Market

  • 25.1. Canada Doxorubicin Market Overview
  • 25.2. Canada Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Doxorubicin Market

  • 26.1. South America Doxorubicin Market Overview
  • 26.2. South America Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Doxorubicin Market

  • 27.1. Brazil Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Doxorubicin Market

  • 28.1. Middle East Doxorubicin Market Overview
  • 28.2. Middle East Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Doxorubicin Market

  • 29.1. Africa Doxorubicin Market Overview
  • 29.2. Africa Doxorubicin Market, Segmentation By Drug Formulation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Doxorubicin Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Doxorubicin Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Doxorubicin Market Competitive Landscape And Company Profiles

  • 30.1. Doxorubicin Market Competitive Landscape
  • 30.2. Doxorubicin Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson and Johnson (Janssen Pharmaceutical)
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Baxter International Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Teva Pharmaceutical Industries Ltd.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Hospira Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Doxorubicin Market Other Major And Innovative Companies

  • 31.1. Dr. Reddy's Laboratories Ltd.
  • 31.2. Cipla Limited
  • 31.3. Hikma Pharmaceuticals
  • 31.4. Mylan Pharmaceuticals Inc.
  • 31.5. VHB Life Sciences Limited
  • 31.6. Xi'an International Healthcare Factory Co.Ltd.
  • 31.7. Accord Healthcare Ltd.
  • 31.8. TTY Biopharm Company Limited
  • 31.9. Cadila Pharmaceuticals
  • 31.10. Neon Laboratories Limited
  • 31.11. Zydus Group
  • 31.12. Ortho Biotech Products LP
  • 31.13. APP Pharmaceuticals Manufacturing LLC
  • 31.14. Sun Pharmaceutical Industries Ltd.
  • 31.15. Transo-Pharm Handels GmbH

32. Global Doxorubicin Market Competitive Benchmarking

33. Global Doxorubicin Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Doxorubicin Market

35. Doxorubicin Market Future Outlook and Potential Analysis

  • 35.1 Doxorubicin Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Doxorubicin Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Doxorubicin Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer